REFERENCES
2. Aziz Q, Thomas AM, Gomes J, et al. The ATP-sensitive potassium channel subunit, Kir6.1, in vascular smooth muscle plays a major role in blood pressure control vascular biology. Vasc Biol 2014;64:523-9.
3. Li A, Knutsen RH, Zhang H, et al. Hypotension due to Kir6.1 gain-of-function in vascular smooth muscle. J Am Heart Assoc 2013;2:e000365.
4. Davis MJ, Kim HJ, Nichols CG. KATP channels in lymphatic function. Am J Physiol Cell Physiol 2022;323:C1018-35.
5. Davis MJ, Castorena-Gonzalez JA, Kim HJ, Li M, Remedi M, Nichols CG. Lymphatic contractile dysfunction in mouse models of Cantú Syndrome with KATP channel gain-of-function. Function 2023;4:zqad017.
6. Alberici LC, Oliveira HC, Paim BA, et al. Mitochondrial ATP-sensitive K+ channels as redox signals to liver mitochondria in response to hypertriglyceridemia. Free Radic Biol Med 2009;47:1432-9.
7. Zhou M, Yoshikawa K, Akashi H, et al. Localization of ATP-sensitive K+ channel subunits in rat liver. World J Exp Med 2019;9:14-31.
8. McTaggart JS, Clark RH, Ashcroft FM. The role of the KATP channel in glucose homeostasis in health and disease: more than meets the islet. J Physiol 2010;588:3201-9.
9. Bennett K, James C, Hussain K. Pancreatic β-cell KATP channels: hypoglycaemia and hyperglycaemia. Rev Endocr Metab Disord 2010;11:157-63.
10. Olson TM, Terzic A. Human KATP channelopathies: diseases of metabolic homeostasis. Pflugers Arch 2010;460:295-306.
11. Nichols CG. Adenosine triphosphate-sensitive potassium currents in heart disease and cardioprotection. Card Electrophysiol Clin 2016;8:323-35.
12. Nichols CG. Personalized therapeutics for KATP-dependent pathologies. Annu Rev Pharmacol Toxicol 2023;63:541-63.
13. Brar PC, Heksch R, Cossen K, et al. Management and appropriate use of diazoxide in infants and children with hyperinsulinism. J Clin Endocrinol Metab 2020;105:3750-61.
14. Lang V, Light PE. The molecular mechanisms and pharmacotherapy of ATP-sensitive potassium channel gene mutations underlying neonatal diabetes. Pharmacogen Pers Med 2010;3:145-61.
15. Kharade SV, Nichols C, Denton JS. The shifting landscape of KATP channelopathies and the need for “sharper” therapeutics. Future Med Chem 2016;8:789-802.
16. Saint-Martin C, Arnoux JB, de Lonlay P, Bellanné-Chantelot C. KATP channel mutations in congenital hyperinsulinism. Semin Pediatr Surg 2011;20:18-22.
17. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004;350:1838-49.
18. Antzelevitch C, Barajas-Martinez H. A gain-of-function I(K-ATP) mutation and its role in sudden cardiac death associated with J-wave syndromes. Heart Rhythm 2010;7:1472-4.
19. Levin MD, Zhang H, Uchida K, Grange DK, Singh GK, Nichols CG. Electrophysiologic consequences of KATP gain of function in the heart: conduction abnormalities in Cantu syndrome. Heart Rhythm 2015;12:2316-24.
20. Baczkó I, Husti Z, Lang V, Leprán I, Light PE. Sarcolemmal KATP channel modulators and cardiac arrhythmias. Curr Med Chem 2011;18:3640-61.
21. Gao J, McClenaghan C, Matreyek KA, Grange DK, Nichols CG. Rapid characterization of the functional and pharmacological consequences of cantú syndrome KATP channel mutations in intact cells. J Pharmacol Exp Ther 2023;386:298-309.
22. Cooper PE, Sala-Rabanal M, Lee SJ, Nichols CG. Differential mechanisms of Cantú syndrome-associated gain of function mutations in the ABCC9 (SUR2) subunit of the KATP channel. J Gen Physiol 2015;146:527-40.
23. McClenaghan C, Nichols CG. Kir6.1 and SUR2B in Cantú syndrome. Am J Physiol Cell Physiol 2022;323:C920-35.
24. Wrzosek A, Augustynek B, Żochowska M, Szewczyk A. Mitochondrial potassium channels as druggable targets. Biomolecules 2020;10:1200.
26. Garlid KD, Paucek P, Yarov-Yarovoy V, et al. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection. Circ Res 1997;81:1072-82.
28. Shake JG, Peck EA, Marban E, et al. Pharmacologically induced preconditioning with diazoxide: a novel approach to brain protection. Ann Thorac Surg 2001;72:1849-54.
29. Caparrelli DJ, Cattaneo Ii SM, Bethea BT, et al. Pharmacological preconditioning ameliorates neurological injury in a model of spinal cord ischemia. Ann Thorac Surg 2002;74:838-45.
31. O’Rourke B. Evidence for mitochondrial K+ channels and their role in cardioprotection. Circ Res 2004;94:420-32.
32. Garlid KD. Opening mitochondrial KATP in the heart - what happens, and what does not happen. Basic Res Cardiol 2000;95:275-9.
33. Garlid KD, Dos Santos P, Xie ZJ, Costa AD, Paucek P. Mitochondrial potassium transport: the role of the mitochondrial ATP-sensitive K+ channel in cardiac function and cardioprotection. Biochim Biophys Acta 2003;1606:1-21.
34. Hu H, Sato T, Seharaseyon J, et al. Pharmacological and histochemical distinctions between molecularly defined sarcolemmal KATP channels and native cardiac mitochondrial KATP channels. Mol Pharmacol 1999;55:1000-5.
35. Gross GJ, Fryer RM. Sarcolemmal versus mitochondrial ATP-sensitive K+ channels and myocardial preconditioning. Circ Res 1999;84:973-9.
36. Kulawiak B, Szewczyk A. Current challenges of mitochondrial potassium channel research. Front Physiol 2022;13:907015.
37. Tseng GN, Hoffman BF. Actions of pinacidil on membrane currents in canine ventricular myocytes and their modulation by intracellular ATP and cAMP. Pflugers Arch 1990;415:414-24.
38. Inagaki N, Gonoi T, Clement JP, et al. A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels. Neuron 1996;16:1011-7.
39. Seino S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu Rev Physiol 1999;61:337-62.
40. Shyng SL, Nichols CG. Octameric stoichiometry of the KATP channel complex. J Gen Physiol 1997;110:655-64.
41. Sellitto AD, Maffit SK, Al-Dadah AS, et al. Diazoxide maintenance of myocyte volume and contractility during stress: evidence for a non-sarcolemmal KATP channel location. J Thorac Cardiovasc Surg 2010;140:1153-9.
42. Garlid KD, Halestrap AP. The mitochondrial KATP channel - fact or fiction? J Mol Cell Cardiol 2012;52:578-83.
43. Hu X, Xu X, Huang Y, et al. Disruption of sarcolemmal ATP-sensitive potassium channel activity impairs the cardiac response to systolic overload. Circ Res 2008;103:1009-17.
44. Flagg TP, Kurata HT, Masia R, et al. Differential structure of atrial and ventricular KATP: atrial KATP channels require SUR1. Circ Res 2008;103:1458-65.
45. Paggio A, Checchetto V, Campo A, et al. Identification of an ATP-sensitive potassium channel in mitochondria. Nature 2019;572:609-13.
46. Garlid KD, Paucek P. Mitochondrial potassium transport: the K+ cycle. Biochim Biophys Acta 2003;1606:23-41.
47. Kravenska Y, Checchetto V, Szabo I. Routes for potassium ions across mitochondrial membranes: a biophysical point of view with special focus on the ATP-sensitive K+ channel. Biomolecules 2021;11:1172.
48. Flagg TP, Enkvetchakul D, Koster JC, Nichols CG. Muscle KATP channels: recent insights to energy sensing and myoprotection. Physiol Rev 2010;90:799-829.
50. Rubin AA, Roth FE, Taylor RM, Rosenkilde H. Pharmacology of diazoxide, an antihypertensive, nondiuretic benzothiadiazine. J Pharmacol Exp Ther 1962;136:344-52. Avaliable from: https://jpet.aspetjournals.org/content/136/3/344.short [Last accessed on 26 Dec 2023].
52. Kumar GK, Dastoor FC, Rodriguez Robayo J, Razzaque MA. Side effects of diazoxide. JAMA 1976;235:275-6.
53. Komatsu Y, Nakamura A, Takihata M, et al. Safety and tolerability of diazoxide in Japanese patients with hyperinsulinemic hypoglycemia. Endocr J 2016;63:311-4.
54. Gray KD, Dudash K, Escobar C, et al. Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee. Prevalence and safety of diazoxide in the neonatal intensive care unit. J Perinatol 2018;38:1496-502.
55. Brito PC, Lopes V, Antunes E, Alves M, Gonçalves I, Matos AC. Hypoglycemia in a non-diabetic patient and the side effects of diazoxide use. Cureus 2023;15:e36804.
56. Quayle JM, Nelson MT, Standen NB. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 1997;77:1165-232.
57. Aziz Q, Li Y, Anderson N, Ojake L, Tsisanova E, Tinker A. Molecular and functional characterization of the endothelial ATP-sensitive potassium channel. J Biol Chem 2017;292:17587-97.
58. Wrzosek A, Gałecka S, Żochowska M, Olszewska A, Kulawiak B. Alternative targets for modulators of mitochondrial potassium channels. Molecules 2022;27:299.
59. Wang J, Papanicolaou K, Tryon R, et al. Kir1.1 and SUR1 are not implicated as subunits of an adenosine triphosphate-sensitive potassium channel involved in diazoxide cardioprotection. JTCVS Open 2023;15:231-41.
60. Anastacio MM, Kanter EM, Makepeace C, et al. Cardioprotective mechanism of diazoxide involves the inhibition of succinate dehydrogenase. Ann Thorac Surg 2013;95:2042-50.
61. Prasad SM, Al-Dadah AS, Byrd GD, et al. Role of the sarcolemmal adenosine triphosphate-sensitive potassium channel in hyperkalemic cardioplegia-induced myocyte swelling and reduced contractility. Ann Thorac Surg 2006;81:148-53.
62. Henn MC, Janjua MB, Kanter EM, et al. Adenosine triphosphate-sensitive potassium channel Kir subunits implicated in cardioprotection by diazoxide. J Am Heart Assoc 2015;4:e002016.
63. Henn MC, Janjua MB, Zhang H, et al. Diazoxide cardioprotection is independent of adenosine triphosphate-sensitive potassium channel Kir6.1 subunit in response to stress. J Am Coll Surg 2015;221:319-25.
64. Sellitto AD, Al-Dadah AS, Schuessler RB, Nichols CG, Lawton JS. An open sarcolemmal adenosine triphosphate-sensitive potassium channel is necessary for detrimental myocyte swelling secondary to stress. Circulation 2011;124:S70-4.
65. Henn MC, Janjua MB, Zhang H, et al. Increased tolerance to stress in cardiac expressed gain-of-function of adenosine triphosphate-sensitive potassium channel subunit Kir6.1. J Surg Res 2016;206:460-5.
66. Wang J, Suarez-Pierre A, Dong J, Lawton JS. Abstract 17206: implication of potassium inward rectifying (Kir1.1) Channel component in cardioprotective mechanism of adenosine triphosphate-sensitive potassium channel opener diazoxide. Circulation 2019;140:A17206. Avaliable from: https://www.ahajournals.org/doi/abs/10.1161/circ.140.suppl_1.17206 [Last accessed on 18 Jan 2024].
67. Rotko D, Kunz WS, Szewczyk A, Kulawiak B. Signaling pathways targeting mitochondrial potassium channels. Int J Biochem Cell Biol 2020;125:105792.
68. Auchampach JA, Grover GJ, Gross GJ. Blockade of ischaemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate downloaded from. Cardiovasc Res 1992;26:1054-62.
69. Shigematsu S, Sato T, Abe T, Saikawa T, Sakata T, Arita M. Pharmacological evidence for the persistent activation of ATP-sensitive K+ channels in early phase of reperfusion and its protective role against myocardial stunning. Circulation 1995;92:2266-75.
70. Galifianes M, Shattock MJ, Hearse DJ. Effects of potassium channel modulation during global ischaemia in isolated rat heart with and without cardioplegia. Cardiovasc Res 1992;26:1063-8.
71. Grover GJ, Sleph PG, Parham CS. Nicorandil Improves postischemic contractile function independently of direct myocardial effects. J Cardiovasc Pharmacol 1990;15:698-705.
72. Pignac J, Bourgouin J, Dumont L. Cold cardioplegia and the K+ channel modulator aprikalim (RP 52891): improved cardioprotection in isolated ischemic rabbit hearts. Can J Physiol Pharmacol 1994;72:126-32.
73. Janjua MB, Makepeace CM, Anastacio MM, Schuessler RB, Nichols CG, Lawton JS. Cardioprotective benefits of adenosine triphosphate-sensitive potassium channel opener diazoxide are lost with administration after the onset of stress in mouse and human myocytes. J Am Coll Surg 2014;219:803-13.
74. Tsuchida A, Miura T, Miki T, et al. Critical timing of mitochondrial K ATP channel opening for enhancement of myocardial tolerance against infarction. Basic Res Cardiol 2001;96:446-53.
75. Kleinbongard P, Lieder H, Skyschally A, Heusch G. Diazoxide is a powerful cardioprotectant but is not feasible in a realistic infarct scenario. Front Cardiovasc Med 2023;10:1173462.
76. Deja MA, Golba KS, Malinowski M, et al. Diazoxide provides maximal KATP channels independent protection if present throughout hypoxia. Ann Thorac Surg 2006;81:1408-16.
77. Mizutani S, Prasad SM, Sellitto AD, Schuessler RB, Damiano RJ Jr, Lawton JS. Myocyte volume and function in response to osmotic stress: observations in the presence of an adenosine triphosphate-sensitive potassium channel opener. Circulation 2005;112:I219-23.
78. Breisblatt WM, Stein KL, Wolfe CJ, et al. Acute myocardial dysfunction and recovery: a common occurrence after coronary bypass surgery. J Am Coll Cardiol 1990;15:1261-9.
79. Velez A, Sebestyen K, Lawton J. A novel, clinically useful definition of myocardial stunning after cardiac surgery. J Am Coll Cardiol 2022;79:1042.
80. Heyndrickx GR, Millard RW, Mcritchie RJ, Maroko PR, Vatner SF. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest 1975;56:978-85.
81. Torregroza C, Raupach A, Feige K, Weber NC, Hollmann MW, Huhn R. Perioperative cardioprotection: general mechanisms and pharmacological approaches. Anesth Analg 2020;131:1765-80.
82. Mizutani S, Al-Dadah AS, Bloch JB, et al. Hyperkalemic cardioplegia-induced myocyte swelling and contractile dysfunction: prevention by diazoxide. Ann Thorac Surg 2006;81:154-9.
83. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-36.
84. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992;70:223-33.
85. Ishida T, Yarimizu K, Gute DC, Korthuis RJ. Mechanisms of ischemic preconditioning. Shock 1994;8:86-94.
86. Wakahara N, Katoh H, Yaguchi Y, et al. Difference in the cardioprotective mechanisms between ischemic preconditioning and pharmacological preconditioning by diazoxide in rat hearts. Circ J 2004;68:156-62.
87. Sutherland FJ, Shattock MJ, Baker KE, Hearse DJ. Mouse isolated perfused heart: characteristics and cautions. Clin Exp Pharmacol Physiol 2003;30:67-78.
88. Motayagheni N. Modified Langendorff technique for mouse heart cannulation: improved heart quality and decreased risk of ischemia. MethodsX 2017;4:508-12.
89. Watanabe M, Okada T. Langendorff perfusion method as an ex vivo model to evaluate heart function in rats. In: Ishikawa K, editor. Experimental models of cardiovascular diseases. New York: Springer; 2018. pp. 107-16.
90. Lawton JS, Hsia PW, Damiano RJ. The adenosine-triphosphate-sensitive potassium-channel opener pinacidil is effective in blood cardioplegia. Ann Thorac Surg 1998;66:768-73.
91. Ledingham S, Braimbridge M, Hearse D. The St. Thomas’ Hospital cardioplegic solution: a comparison of the efficacy of two formulations. J Thorac Cardiovasc Surg 1987;93:240-6.
92. Lawton JS, Sepic JD, Allen CT, Hsia PW, Damiano RJ. Myocardial protection with potassium-channel openers is as effective as St. Thomas’ solution in the rabbit heart. Ann Thorac Surg 1996;62:31-9.
93. Lawton JS, Harrington GC, Allen CT, Hsia PW, Damiano RJ. Myocardial protection with pinacidil cardioplegia in the blood-perfused heart. Ann Thorac Surg 1996;61:1680-8.
94. Lawton JS, Hsia PW, Allen CT, Damiano RJ. Myocardial protection in the acutely injured heart: hyperpolarizing versus depolarizing hypothermic cardioplegia. J Thorac Cardiovasc Surg 1997;113:567-75.
95. Garlid KD, Paucek P, Yarov-Yarovoy V, Sun X, Schindler PA. The mitochondrial KATP channel as a receptor for potassium channel openers. J Biol Chem 1996;271:8796-9.
96. Andersson KE. Clinical pharmacology of potassium channel openers. Pharmacol Toxicol 1992;70:244-54.
97. Faivre JF, Findlay I. Effects of tolbutamide, glibenclamide and diazgxide upon action potentials recorded from rat ventricular muscle. Biochim Biophys Acta Bioenerg 1989;984:1-5.
98. Lascano EC, Negroni JA, Del Valle HF. Ischemic shortening of action potential duration as a result of KATP channel opening attenuates myocardial stunning by reducing calcium influx. Mol Cell Biochem 2002;236:53-61.
99. Inoue I, Nagase H, Kishi K, Higuti T. ATP-sensitive K+ channel in the mitochondrial inner membrane. Nature 1991;352:244-7.
100. Rousou AJ, Ericsson M, Federman M, Levitsky S, Mccully JD. Opening of mitochondrial KATP channels enhances cardioprotection through the modulation of mitochondrial matrix volume, calcium accumulation, and respiration. Am J Physiol Heart Circ Physiol 2004;287:1967-76.
101. Nakai Y, Horimoto H, Mieno S, Sasaki S. Mitochondrial ATP-sensitive potassium channel plays a dominant role in ischemic preconditioning of rabbit heart. Eur Surg Res 2001;33:57-63.
102. Coetzee WA. Multiplicity of effectors of the cardioprotective agent, diazoxide. Pharmacol Ther 2013;140:167-75.
103. Anastacio MM, Kanter EM, Makepeace CM, et al. Relationship between mitochondrial matrix volume and cellular volume in response to stress and the role of ATP-sensitive potassium channel. Circulation 2013;128:S130-5.
104. Murata M, Akao M, O’Rourke B, Marbán E. Mitochondrial ATP-sensitive potassium channels attenuate matrix Ca2+ overload during simulated ischemia and reperfusion: possible mechanism of cardioprotection. Circ Res 2001;89:891-8.
105. Steenbergen C, Hill ML, Jennings RB. Volume regulation and plasma membrane injury in aerobic, anaerobic, and ischemic myocardium in vitro. Effects of osmotic cell swelling on plasma membrane integrity. Circ Res 1985;57:864-75.
106. Al-Dadah AS, Voeller RK, Schuessler RB, Damiano RJ Jr, Lawton JS. Maintenance of myocyte volume homeostasis during stress by diazoxide is cardioprotective. Ann Thorac Surg 2007;84:857-62.
107. Maffit SK, Sellitto AD, Al-Dadah AS, Schuessler RB, Damiano RJ Jr, Lawton JS. Diazoxide maintains human myocyte volume homeostasis during stress. J Am Heart Assoc 2012;1:e000778.
108. Zhang HX, Akrouh A, Kurata HT, Remedi MS, Lawton JS, Nichols CG. HMR 1098 is not an SUR isotype specific inhibitor of heterologous or sarcolemmal KATP channels. J Mol Cell Cardiol 2011;50:552-60.
109. Suzuki M, Saito T, Sato T, et al. Cardioprotective effect of diazoxide is mediated by activation of sarcolemmal but not mitochondrial ATP-sensitive potassium channels in mice. Circulation 2003;107:682-5.
110. Wojtovich AP, Brookes PS. The endogenous mitochondrial complex II inhibitor malonate regulates mitochondrial ATP sensitive potassium channels: implications for ischemic preconditioning. Biochim Biophys Acta 2008;1777:882-9.
111. Ardehali H, Chen Z, Ko Y, Mejía-Alvarez R, Marbá E. Multiprotein complex containing succinate dehydrogenase confers mitochondrial ATP-sensitive K+ channel activity. Proc Natl Acad Sci 2004;101:11880-5.
112. Krenz M, Oldenburg O, Wimpee H, et al. Opening of ATP-sensitive potassium channels causes generation of free radicals in vascular smooth muscle cells. Basic Res Cardiol 2002;97:365-73.
113. Zeng WZ, Liou HH, Murali Krishna U, Falck JR, Huang CL. Structural determinants and specificities for ROMK1-phosphoinositide interaction. Am J Physiol-Renal 2002;282:826-34.
114. Forbes RA, Steenbergen C, Murphy E. Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism. Circ Res 2001;88:802-9.
115. Carroll R, Gant VA, Yellon DM. Mitochondrial KATP channel opening protects a human atrial-derived cell line by a mechanism involving free radical generation. Cardiovasc Res 2001;51:691-700.
116. Oldenburg O, Yang XM, Krieg T, et al. P1075 opens mitochondrial KATP channels and generates reactive oxygen species resulting in cardioprotection of rabbit hearts. J Mol Cell Cardiol 2003;35:1035-42.
117. Garlid AO, Jaburek M, Jacobs JP, Garlid KD. Mitochondrial reactive oxygen species: which ROS signals cardioprotection? J Physiol Heart Circ Physiol 2013;305:960-8.
118. Dröse S, Brandt U, Hanley PJ. K+-independent actions of diazoxide question the role of inner membrane KATP channels in mitochondrial cytoprotective signaling. J Biol Chem 2006;281:23733-9.
119. Hanley PJ, Mickel M, Löffler M, Brandt U, Daut J. KATP channel-independent targets of diazoxide and 5-hydroxydecanoate in the heart. J Physiol 2002;542:735-41.
120. Dzeja PP, Bast P, Ozcan C, et al. Targeting nucleotide-requiring enzymes: implications for diazoxide-induced cardioprotection. Am J Physiol Heart Circ Physiol 2003;284:1048-56.
121. Ockaili RA, Bhargava P, Kukreja RC. Chemical preconditioning with 3-nitropropionic acid in hearts: role of mitochondrial KATP channel. J Physiol Heart Circ Physiol 2001;280:2406-11.
122. Busija DW, Katakam P, Rajapakse NC, et al. Effects of ATP-sensitive potassium channel activators diazoxide and BMS-191095 on membrane potential and reactive oxygen species production in isolated piglet mitochondria. Brain Res Bull 2005;66:85-90.
123. Chouchani ET, Pell VR, Gaude E, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature 2014;515:431-5.
124. Anastacio MM, Kanter EM, Keith AD, Schuessler RB, Nichols CG, Lawton JS. Inhibition of succinate dehydrogenase by diazoxide is independent of the ATP-sensitive potassium channel subunit sulfonylurea type 1 receptor. J Am Coll Surg 2013;216:1144-9.
125. Eaton M, Hernandez LA, Schaefer S. Ischemic preconditioning and diazoxide limit mitochondrial Ca2+ overload during ischemia/reperfusion: role of reactive oxygen species. Exp Clin Cardiol 2005;10:96-103.
126. Ahmad T, Wang J, Velez AK, et al. Cardioprotective mechanisms of mitochondria-targeted S-nitrosating agent and adenosine triphosphate-sensitive potassium channel opener are mutually exclusive. JTCVS Open 2021;8:338-54.
127. Uchiyama Y, Otani H, Okada T, et al. Integrated pharmacological preconditioning in combination with adenosine, a mitochondrial KATP channel opener and a nitric oxide donor. J Thorac Cardiovasc Surg 2003;126:148-59.
128. Kim MY, Kim MJ, Yoon IS, et al. Diazoxide acts more as a PKC-epsilon activator, and indirectly activates the mitochondrial KATP channel conferring cardioprotection against hypoxic injury. Br J Pharmacol 2006;149:1059-70.
129. Akao M, Ohler A, O’rourke B, Marbán E. Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells. Circ Res 2001;88:1267-75.
130. Yonemochi H, Ichinose M, Anan F, et al. Diazoxide-induced cardioprotection via DeltaPsim loss depending on timing of application. Life Sci 2006;79:1906-12.
131. Mccully JD, Wakiyama H, Cowan DB, Federman M, Parker RA, Levitsky S. Diazoxide amelioration of myocardial injury and mitochondrial damage during cardiac surgery. Ann Thorac Surg 2002;74:2138-46.
132. Maslov LN, Popov SV, Naryzhnaya NV, et al. KATP channels are regulators of programmed cell death and targets for the creation of novel drugs against ischemia/reperfusion cardiac injury. Fundam Clin Pharmacol 2023;37:1020-49.
133. Davies JE, Digerness SB, Killingsworth CR, et al. Multiple treatment approach to limit cardiac ischemia-reperfusion injury. Ann Thorac Surg 2005;80:1408-16.
134. Makepeace CM, Suarez-Pierre A, Kanter EM, Schuessler RB, Nichols CG, Lawton JS. Superior diastolic function with KATP channel opener diazoxide in a novel mouse Langendorff model. J Surg Res 2018;227:186-93.
135. Suarez-Pierre A, Lui C, Zhou X, et al. Diazoxide preserves myocardial function in a swine model of hypothermic cardioplegic arrest and prolonged global ischemia. J Thorac Cardiovasc Surg 2022;163:e385-400.
136. Velez AK, Etchill E, Giuliano K, et al. ATP - sensitive potassium channel opener diazoxide reduces myocardial stunning in a porcine regional with subsequent global ischemia model. J Am Heart Assoc 2022;11:e026304.
137. Wang X, Wei M, Kuukasjärvi P, et al. Novel pharmacological preconditioning with diazoxide attenuates myocardial stunning in coronary artery bypass grafting. Eur J Cardiothorac Surg 2003;24:967-73.
138. Deja MA, Malinowski M, Gołba KS, et al. Diazoxide protects myocardial mitochondria, metabolism, and function during cardiac surgery: a double-blind randomized feasibility study of diazoxide-supplemented cardioplegia. J Thorac Cardiovasc Surg 2009;137:997-1004.
139. Ziganshin BA, Elefteriades JA. Deep hypothermic circulatory arrest. Ann Cardiothorac Surg 2013;2:303-15.
140. Wang X, Yang F, Zhu J, Liu Y, Sun L, Hou X. Aortic arch surgery with hypothermic circulatory arrest and unilateral antegrade cerebral perfusion: perioperative outcomes. J Thorac Cardiovasc Surg 2020;159:374-87.e4.
141. Bergeron EJ, Mosca MS, Aftab M, Justison G, Reece TB. Neuroprotection strategies in aortic surgery. Cardiol Clin 2017;35:453-65.
142. Giuliano K, Etchill E, Velez AK, et al. Ketamine mitigates neurobehavioral deficits in a canine model of hypothermic circulatory arrest. Semin Thorac Cardiovasc Surg 2023;35:251-8.
143. Honrath B, Krabbendam IE, Culmsee C, Dolga AM. Small conductance Ca2+-activated K+ channels in the plasma membrane, mitochondria and the ER: pharmacology and implications in neuronal diseases. Neurochem Int 2017;109:13-23.
144. Debska G, May R, Kicinska A, Szewczyk A, Elger CE, Kunz WS. Potassium channel openers depolarize hippocampal mitochondria. Brain Res 2001;892:42-50.
145. De Arriba S, Franke H, Pissarek M, Nieber K, Illes P. Neuroprotection by ATP-dependent potassium channels in rat neocortical brain slices during hypoxia. Neurosci Lett 1999;273:13-6.
146. Domoki F, Perciaccante JV, Veltkamp R, Bari F, Busija DW. Mitochondrial Potassium channel opener diazoxide preserves neuronal-vascular function after cerebral ischemia in newborn pigs. Stroke 1999;30:2713-9.
147. Barreiro CJ, Williams JA, Fitton TP, et al. Noninvasive assessment of brain injury in a canine model of hypothermic circulatory arrest using magnetic resonance spectroscopy. Ann Thorac Surg 2006;81:1593-8.
148. Teshima Y, Akao M, Li RA, et al. Mitochondrial ATP-sensitive potassium channel activation protects cerebellar granule neurons from apoptosis induced by oxidative stress. Stroke 2003;34:1796-802.
149. Fatemi A, Wilson MA, Johnston MV. Hypoxic-ischemic encephalopathy in the term infant. Clin Perinatol 2009;36:835-58, vii.
150. Yamanaka K, Eldeiry M, Aftab M, et al. Pretreatment with diazoxide attenuates spinal cord ischemia-reperfusion injury through signaling transducer and activator of transcription 3 pathway. Ann Thorac Surg 2019;107:733-9.
151. Yamanaka K, Eldeiry M, Aftab M, et al. Synergistic reduction of apoptosis with diazoxide and erythropoietin in spinal cord ischemic injury. Ann Thorac Surg 2018;106:1751-8.
152. Yamanaka K, Eldeiry M, Aftab M, et al. Synergetic induction of NGF with diazoxide and erythropoietin attenuates spinal cord ischemic injury. J Surg Res 2019;233:124-31.
